Linda Filler, a director at Danaher Corporation, exercised director stock options and acquired common stock on July 15, 2026, according to a regulatory disclosure filed with the Securities and Exchange Commission. The transactions involved the exercise of 3,298 director options at an exercise price of $71.88 per share and the acquisition of 1,181 shares of common stock at $200.79 per share. The filing reveals Filler's current beneficial ownership position in the Delaware-incorporated life sciences and diagnostics conglomerate.

Key Points

  • NYSE: DHR
  • Director Linda Filler exercised 3,298 director stock options on July 15, 2026, with an exercise price of $71.88 per share
  • Filler acquired 1,181 common shares at $200.79 per share on the same date
  • Following the transactions, Filler held 28,010.403 shares directly and 21,590 shares indirectly through a trust

Director Option Exercise at Danaher

On July 15, 2026, Linda Filler executed the exercise of director stock options representing the right to purchase 3,298 shares of Danaher common stock. The exercise price for these options was established at $71.88 per share. The options had an original grant date of July 15, 2016, with an expiration date of July 15, 2026, meaning the exercise occurred on the final day before the options would have expired. This timing reflects a standard practice whereby directors exercise vesting awards prior to their maturation dates.

Director stock options are a common component of board compensation structures within the life sciences and diagnostics industry. Danaher, which maintains operations across environmental and applied solutions, life sciences and diagnostics, and diagnostics segments, uses equity-based compensation to align director interests with shareholder value. The exercise of these options by Filler expanded her direct beneficial ownership position in the company and demonstrates her continued investment in Danaher's future performance.

Additional Common Stock Acquisition by Filler

Beyond the option exercise, Filler also acquired 1,181 shares of Danaher common stock on July 15, 2026, at a price of $200.79 per share. This acquisition represented a separate transaction conducted on the same date as the option exercise. The higher per-share price of the common stock acquisition compared to the director option exercise price reflects the different nature and timing of these two equity transactions.

The acquisition of additional shares through direct purchase demonstrates an insider's confidence in the company's business prospects. Danaher's diversified portfolio spans critical areas including life sciences tools, environmental monitoring, product identification, and quality and safety solutions. Director and officer purchases of company shares are often viewed by investors as signals of management's outlook regarding the company's valuation and near-term performance trajectory.

Beneficial Ownership Following the July 2026 Transactions

Following the completion of both transactions on July 15, 2026, Filler's beneficial ownership statement reflects a direct holding of 28,010.403 shares of Danaher common stock. This direct holding represents shares owned in Filler's own name. In addition to her direct ownership, Filler maintains an indirect beneficial ownership position of 21,590 shares held through a trust arrangement, as disclosed in the filing.

Beneficial ownership calculations include both shares held directly and those held indirectly through entities such as trusts, family partnerships, or other legal structures. The distinction between direct and indirect ownership is significant for regulatory and disclosure purposes, as insider holdings above certain thresholds trigger enhanced reporting obligations and trading restrictions. The filing presents Filler's complete ownership picture as of the transaction date, providing transparency regarding her financial stake in Danaher's equity.

Danaher's Business Operations and Market Position

Danaher Corporation operates as a Delaware corporation engaged in the design, manufacture, and marketing of industrial and commercial products and services across multiple sectors. The company's operating model emphasizes engineered products, software, and services that serve environmental monitoring, life sciences research, diagnostics, and product identification markets. These segments position Danaher within the broader scientific instruments, diagnostics, and laboratory equipment sectors, which have experienced sustained demand from research institutions, healthcare systems, and industrial manufacturers.

The company's diversified revenue base and market exposure across life sciences, diagnostics, and environmental solutions has historically insulated Danaher from volatility in individual end-markets. Director participation in equity ownership programs, such as the exercise of options by Filler, reflects confidence in the company's ability to generate long-term shareholder returns across these business segments. Insider transactions are monitored by investors and analysts as indicators of management's assessment of company valuation relative to current trading levels.

Regulatory Framework for Director Equity Transactions

Transactions involving directors and officers of publicly traded companies are subject to Section 16 of the Securities Exchange Act of 1934, which requires disclosure of beneficial ownership changes. The Form 4 filing completed on July 16, 2026, one business day after the July 15 transaction date, meets the regulatory requirement for timely reporting of insider transactions. These disclosures are made publicly available through the Securities and Exchange Commission's EDGAR database, providing transparency to investors regarding insider trading activity.

Director stock option plans and equity purchase programs are designed to align director compensation with shareholder interests while retaining experienced board members. The two-year window between the July 2016 grant date and the July 2026 exercise date for Filler's options reflects the vesting schedule typically embedded in director equity awards. Understanding the timing and structure of these transactions aids investors in evaluating board-level confidence in company management and strategic direction.

Comparison of Exercise Price to Market Conditions

The director option exercise price of $71.88 per share established on the July 15, 2016 grant date provided a baseline for Filler's July 15, 2026 exercise decision. The subsequent common stock acquisition at $200.79 per share on the same day reflects the market price at which shares traded during the transaction. The significant difference between these two prices indicates substantial appreciation in Danaher's stock value over the ten-year period from the initial grant through the exercise date.

The relationship between exercise prices, market prices, and insider decision-making is closely observed by market participants. When directors and officers exercise options or purchase shares, the timing and context of these transactions inform investor analysis regarding insider sentiment about valuation levels. However, it should be noted that the filing documents specific transactions without providing forward-looking statements or management guidance regarding future share price expectations.

Insider Reporting Requirements and Compliance

The disclosure was signed on behalf of Linda Filler by James F. O'Reilly, identified as attorney-in-fact, on July 16, 2026. This authorization represents Filler's delegation of signature authority to O'Reilly for filing purposes, a common practice in corporate governance. The prompt filing of the Form 4 within the required timeframe demonstrates compliance with Securities and Exchange Commission reporting obligations applicable to directors and substantial shareholders.

Compliance with Section 16 reporting rules is mandatory for all directors, officers, and beneficial owners exceeding the five percent threshold. Failure to comply with these requirements can result in penalties and enforcement actions. The timely and complete disclosure of Filler's transactions provides the market with accurate information regarding insider ownership changes at Danaher, supporting informed investment decision-making by shareholders and prospective investors.

Market Context for Life Sciences and Diagnostics Sector

Danaher's position within the life sciences tools, diagnostics, and environmental solutions markets places the company in sectors that have experienced sustained investment focus. These markets serve research institutions, hospitals, clinical laboratories, and industrial manufacturers requiring specialized equipment and reagents. Director participation in equity ownership programs occurs within the context of these broader sector dynamics and the company's competitive positioning relative to peer organizations.

The timing of Filler's equity transactions, occurring in mid-July 2026, reflects normal course option exercise activity coinciding with grant anniversaries and expiration dates. Insider trading activity during periods of significant market volatility or company-specific developments receives heightened scrutiny from regulators and investors. The absence of any disclosure regarding trading restrictions or blackout periods in the filing suggests the transactions occurred during an open window for insider trading under Danaher's trading policies.